Compare CPSS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | KZIA |
|---|---|---|
| Founded | 1991 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 186.7M |
| IPO Year | 2010 | 2002 |
| Metric | CPSS | KZIA |
|---|---|---|
| Price | $9.56 | $9.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 21.8K | ★ 378.8K |
| Earning Date | 05-11-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.27 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $434,470,000.00 | N/A |
| Revenue This Year | $147.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.74 | ★ N/A |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $7.34 | $4.86 |
| 52 Week High | $10.49 | $17.40 |
| Indicator | CPSS | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 35.92 |
| Support Level | $8.97 | $5.15 |
| Resistance Level | $9.66 | $14.85 |
| Average True Range (ATR) | 0.33 | 0.79 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 75.00 | 16.18 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.